GH Research is trading at $19.31, up 5.63%, apparently in line with biotech-sector strength; no direct company-specific cause has been identified.
- XBI rose 2.10% during regular trading. No new GH Research-specific catalyst surfaced for October 20; the available company update is dated August 6.
- Sector sentiment also drew support from Merck KGaA’s agreement to acquire Silence Therapeutics for about $1.3 billion, alongside positive biotech clinical-trial news.